PMID- 36938780
OWN - NLM
STAT- MEDLINE
DCOM- 20240126
LR  - 20240206
IS  - 1445-5994 (Electronic)
IS  - 1444-0903 (Linking)
VI  - 54
IP  - 1
DP  - 2024 Jan
TI  - Administration of intravenous iron through a home-based infusion strategy is safe 
      and has high patient acceptance.
PG  - 104-107
LID - 10.1111/imj.16075 [doi]
AB  - BACKGROUND AND AIMS: To evaluate the safety and patient experience of a 
      hospital-initiated home-based iron infusion service in patients with iron 
      deficiency with or without anaemia. METHODS: Retrospective cohort study, 
      including adult patients who received intravenous iron through a Hospital in The 
      Home service in a single tertiary centre between August 2020 and 2021. A chart 
      review was conducted for documented adverse events (AEs). A telephone survey 
      assessed patient acceptance with three questions on a 5-point Likert scale: (i) 
      How do you perceive the experience of having your infusion given in the home? 
      (ii) Would you like to have the infusion in the same location if you require one 
      in the future? and (iii) Do you feel safe having your infusion at home? OUTCOME 
      MEASURES: Percentage of patients experiencing AEs and patient acceptance of a 
      home-based iron infusion strategy. RESULTS: One hundred ninety-seven patients 
      were included (181 ferric carboxymaltose and 16 ferric derisomaltose). Six (3%) 
      patients (2 of 181 patients who received ferric carboxymaltose compared with 4 of 
      16 patients who received ferric derisomaltose, P < 0.001, Fisher's exact) 
      experienced AEs, mostly headache and pruritus. Most patients who participated in 
      the telephone survey had a positive experience (57/58 (98%)), felt safe (57/58 
      (98%)) and preferred future infusions to occur at home (52/58 (90%)). CONCLUSION: 
      A home-based iron infusion strategy was safe and well accepted by patients. 
      Larger studies evaluating the safety profile of different iron formulations in 
      the home setting are required.
CI  - (c) 2023 Royal Australasian College of Physicians.
FAU - Liu, Dorothy
AU  - Liu D
AUID- ORCID: 0000-0002-7802-2803
AD  - Department of Gastroenterology, Northern Health, Melbourne, Victoria, Australia.
FAU - Atienza, Eloisa
AU  - Atienza E
AD  - Department of Gastroenterology, Northern Health, Melbourne, Victoria, Australia.
FAU - Santamaria, Lynne
AU  - Santamaria L
AD  - Hospital in the Home Service, Northern Health, Melbourne, Victoria, Australia.
FAU - Sinnappu, Rabin
AU  - Sinnappu R
AD  - Hospital in the Home Service, Northern Health, Melbourne, Victoria, Australia.
FAU - Garg, Mayur
AU  - Garg M
AD  - Department of Gastroenterology, Northern Health, Melbourne, Victoria, Australia.
AD  - Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
LA  - eng
PT  - Journal Article
DEP - 20230331
PL  - Australia
TA  - Intern Med J
JT  - Internal medicine journal
JID - 101092952
RN  - E1UOL152H7 (Iron)
RN  - AHU547PI9H (ferric derisomaltose)
RN  - 6897GXD6OE (ferric carboxymaltose)
RN  - 0 (Disaccharides)
RN  - 0 (Ferric Compounds)
RN  - 69-79-4 (Maltose)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Iron/adverse effects
MH  - *Anemia, Iron-Deficiency/drug therapy
MH  - Retrospective Studies
MH  - Administration, Intravenous
MH  - Infusions, Intravenous
MH  - *Disaccharides
MH  - *Ferric Compounds
MH  - Maltose/*analogs & derivatives
OTO - NOTNLM
OT  - ferric carboxymaltose
OT  - ferric derisomaltose
OT  - iron deficiency
OT  - iron deficiency anaemia
OT  - iron infusion
EDAT- 2023/03/21 06:00
MHDA- 2024/01/26 06:44
CRDT- 2023/03/20 05:12
PHST- 2022/12/19 00:00 [received]
PHST- 2023/03/15 00:00 [accepted]
PHST- 2024/01/26 06:44 [medline]
PHST- 2023/03/21 06:00 [pubmed]
PHST- 2023/03/20 05:12 [entrez]
AID - 10.1111/imj.16075 [doi]
PST - ppublish
SO  - Intern Med J. 2024 Jan;54(1):104-107. doi: 10.1111/imj.16075. Epub 2023 Mar 31.